AtremoPlus Natural L-Dopa: Incredible stability!

In our latest newsletter, we discussed our commitment to understanding the mechanisms of action and measuring key parameters and biomarkers. This approach allows us to quantify the concrete impact on motor and cognitive performance, with observable effects shortly after initial intake.

In this new edition, we aim to explore how these enhanced biomarkers also affect our bodies in the long term. Users of AtremoPlus report rapid effects across all areas related to dopamine deficiency, but what about long-term effects?

The first part will present these stability effects through one of our many testimonials. Today, we can draw conclusions from effects observed over several years, approaching a decade.

In the second part, we will delve into how stability constitutes the third phase of improvements observed with Atremoplus.

Finally, in the third part, we will attempt to understand some of the mechanisms that may underpin long-term stability.

1 – Long-term stability effects observed following AtremoPlus intake

Stability has been a topic of focus for us for several years now. Specifically, since about 4-5 years ago when we started receiving testimonials from our customers saying, “My neurologist is surprised because for the past 3 years that I’ve been taking AtremoPlus, there has been no need to increase my dose of chemical L-dopa, and I am doing well.”

Over time, the phenomenon of stability has gained momentum, and every week individuals share their joy in observing that their condition has remained relatively stable since starting AtremoPlus.

In the initial phase following the launch of our plant-based L-dopa/Carbidopa in 2016, our focus was primarily on rapid and immediate effects. Even though preclinical studies had indicated a strong potential for antioxidant protection, suggesting long-term stability for individuals, our priority was to communicate these rapid and immediate effects.

A typical testimonial illustrating stability

This week, during a discussion with a former client who said to us, “(…) but imagine how wonderful it is!” it became evident to us that we should communicate more about this other benefit of AtremoPlus.

Let’s focus on the case of this person whom we warmly thank and who will certainly recognize herself.

More than three years ago, her husband began to show small signs of Parkinson’s, such as a decrease in fine motor skills with a lack of precision in his movements and occasional slight tremors.

Their doctor, not wanting to prescribe treatment at this stage, found AtremoPlus, the plant-based variant of L-Dopa/Carbidopa, online. Before ordering, they asked the doctor if taking AtremoPlus would be appropriate, and he confirmed that it could be beneficial.

Since then, she has observed with helplessness how some of her friends with Parkinson’s, who do not take AtremoPlus, deteriorate rapidly, while her husband remains stable.

One of our arguments that also motivated them to try was, “if after a month, you do not experience the expected effects, it’s not worth continuing.”

We acknowledge today that this information is incomplete. Although most people feel the effects within the first four weeks of taking 10g of AtremoPlus per day, this perspective remains limited as it does not consider the medium and long-term effects that we observe over time (see below).

Since her husband did not have major symptoms, he has only been taking 2 scoops in the morning for three and a half years. Not only does he feel better, being more confident and precise in his movements, but they also note that his situation has been stable all these years. Hence his words on the phone, “imagine how wonderful it is!”

2 – Stability is the third phase of improvements observed with AtremoPlus.

As a degenerative and incurable disease, during the diagnosis of Parkinson’s disease, it is usually explained that medications are effective initially, a phase referred to by doctors as the “honeymoon period,” but they gradually lose their effectiveness on average after 3 to 5 years.

Scientists tell us that this is due, among other factors, to the continued degeneration of dopaminergic neurons in the brains of those affected, thereby reducing the brain’s capacity to produce dopamine and necessitating a greater external supply of L-dopa. Other reasons are also cited, such as decreased absorption capabilities due to various physiological dysfunctions. Eventually, doctors say they reach the limit of the prescribed doses of chemical L-dopa that the body can support. The patient then enters, more or less quickly, into more advanced stages of Parkinson’s disease, with an increase in disease-related symptoms and side effects listed in medication leaflets.

Of course, each situation is individual, and there are certainly as many variations of Parkinson’s as there are people with Parkinson’s, but this is a trend generally observed in science.

For this reason, we are frequently asked if AtremoPlus is like chemical L-dopa, where initially everything goes well and then the effect of L-dopa diminishes more or less rapidly. Our answer is no. With an 8-year perspective, it is remarkable to note that the phenomenon of progressive loss of effectiveness is generally not observed with the active principles of naturally occurring L-dopa/Carbidopa found in the Vicia faba plant.

The 3 phases of improvements: short term, medium term, and long term

People using AtremoPlus share their experiences with us, and our surveys also provide valuable insights. Although each situation is unique, we generally observe improvements in the short term, medium term, and long term:

1. Short-term phase: This phase typically involves a rapid and noticeable improvements in most motor, cognitive, and energetic parameters. For some, these improvements are evident from the first hours of intake, while for others, it may take between 2 to 4 weeks. There may be resistance in specific areas, but overall, the situation improves significantly. This initial phase serves as an excellent indicator of short-term expectations and is linked to users’ ability to metabolize naturally sourced L-dopa/Carbidopa.
    
2. Medium-term phase: During this phase, lasting approximately 6 to 12 months, additional improvements usually manifest, driven by a virtuous cycle. A synergy develops as feeling more energy and motivation encourages increased activity, leading to progress and better prospects. This encourages even more activities and so on. With the right active principles, these achievements often become more attainable. People are more inclined to act out of a desire to undertake activities rather than an obligation to move.
    
3. Long-term phase: We increasingly receive feedback on this phase, characterized by stability over extended periods, up to 8 years for our longest-standing users. They report having regained a better and lasting quality of life. Even their neurologists are pleased to note that after an initial gradual reduction of chemical L-Dopa by approximately 25-50%, their patients remain very stable over long periods without needing dosage adjustments. They are relatively well, some even very well, considering the circumstances.

We emphasize that this is a general observation based on feedback from many AtremoPlus users and some of their neurologists. We do not seek to generalize these results as each situation is individual and influenced by numerous factors affecting health and aging. Each experience with our product is unique. Additionally, we do not claim here that Parkinson’s disease is curable.

However, we align with the latest scientific discoveries, particularly in neuroscience, which increasingly reveal the phenomenon of brain plasticity. See below.

3 – The mechanisms that could be behind long-term stability

A. Reduction of Oxidation

The first notable characteristic is undoubtedly the powerful antioxidant effect of the active principles extracted from the Vicia faba plant. AtremoPlus not only provides L-dopa/Carbidopa but also harnesses the recognized antioxidant properties of these active principles, extensively documented by scientific teams worldwide. Regulatory restrictions prevent us from specifically mentioning them on the label due to their individually low concentrations, but their synergy is essential.

Among the components we can mention are amino acids, polyphenols, carotenoids, flavonoids, minerals such as zinc, manganese, as well as vitamins A, B, C, D, and E. The latter is present to meet the recommended daily dose and is recognized for its antioxidant properties by regulatory authorities.

Essentially, these antioxidants help reduce oxidation in the body. This natural process generates free radicals that over time damage healthy tissues, including neurons. With age, this phenomenon can accelerate, necessitating antioxidants that, by transferring excess electrons, neutralize free radicals before they cause harm.

For those of you who have not yet watched our video on this fundamental topic, which helps understand an important parameter of degeneration and Parkinson’s disease, you can view it by clicking here.